M Dong1, C Fisher1, G Añez1, M Rios1, H L Nakhasi1, J P Hobson2, M Beanan3, D Hockman4, E Grigorenko4, R Duncan1. 1. Laboratory of Emerging Pathogens, Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, MD, USA. 2. Office of In Vitro Diagnostics and Radiological Health (OIR), Division of Microbiology Devices, Center for Devices and Radiological Health (CDRH), FDA, Silver Spring, MD, USA. 3. Office of Biodefense, Research Resources, and Translational Research, Division of Microbiology and Infectious Diseases (DMID), National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, USA. 4. Diatherix Laboratory, Huntsville, AL, USA.
Abstract
AIMS: To demonstrate standardized methods for spiking pathogens into human matrices for evaluation and comparison among diagnostic platforms. METHODS AND RESULTS: This study presents detailed methods for spiking bacteria or protozoan parasites into whole blood and virus into plasma. Proper methods must start with a documented, reproducible pathogen source followed by steps that include standardized culture, preparation of cryopreserved aliquots, quantification of the aliquots by molecular methods, production of sufficient numbers of individual specimens and testing of the platform with multiple mock specimens. Results are presented following the described procedures that showed acceptable reproducibility comparing in-house real-time PCR assays to a commercially available multiplex molecular assay. CONCLUSIONS: A step by step procedure has been described that can be followed by assay developers who are targeting low prevalence pathogens. SIGNIFICANCE AND IMPACT OF THE STUDY: The development of diagnostic platforms for detection of low prevalence pathogens such as biothreat or emerging agents is challenged by the lack of clinical specimens for performance evaluation. This deficit can be overcome using mock clinical specimens made by spiking cultured pathogens into human matrices. To facilitate evaluation and comparison among platforms, standardized methods must be followed in the preparation and application of spiked specimens. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.
AIMS: To demonstrate standardized methods for spiking pathogens into human matrices for evaluation and comparison among diagnostic platforms. METHODS AND RESULTS: This study presents detailed methods for spiking bacteria or protozoan parasites into whole blood and virus into plasma. Proper methods must start with a documented, reproducible pathogen source followed by steps that include standardized culture, preparation of cryopreserved aliquots, quantification of the aliquots by molecular methods, production of sufficient numbers of individual specimens and testing of the platform with multiple mock specimens. Results are presented following the described procedures that showed acceptable reproducibility comparing in-house real-time PCR assays to a commercially available multiplex molecular assay. CONCLUSIONS: A step by step procedure has been described that can be followed by assay developers who are targeting low prevalence pathogens. SIGNIFICANCE AND IMPACT OF THE STUDY: The development of diagnostic platforms for detection of low prevalence pathogens such as biothreat or emerging agents is challenged by the lack of clinical specimens for performance evaluation. This deficit can be overcome using mock clinical specimens made by spiking cultured pathogens into human matrices. To facilitate evaluation and comparison among platforms, standardized methods must be followed in the preparation and application of spiked specimens. Published 2016. This article is a U.S. Government work and is in the public domain in the USA.
Authors: R Duncan; R Alvarez; C L Jaffe; M Wiese; M Klutch; A Shakarian; D Dwyer; H L Nakhasi Journal: Parasitol Res Date: 2001-11 Impact factor: 2.289
Authors: A Selvapandiyan; R Duncan; A Debrabant; S Bertholet; G Sreenivas; N S Negi; P Salotra; H L Nakhasi Journal: J Biol Chem Date: 2001-09-05 Impact factor: 5.157
Authors: Donna Hockman; Ming Dong; Hong Zheng; Sanjai Kumar; Matthew D Huff; Elena Grigorenko; Maureen Beanan; Robert Duncan Journal: J Microbiol Methods Date: 2016-11-09 Impact factor: 2.363
Authors: Shivani G Beall; Jason Cantera; Maureen H Diaz; Jonas M Winchell; Lorraine Lillis; Heather White; Michael Kalnoky; James Gallarda; David S Boyle Journal: PLoS One Date: 2019-04-18 Impact factor: 3.240